Almirall’s Post

Discover our latest case study that delves into the complexities of a large-scale global Phase III Biosimilar Dermatology Trial. The study showcases how COD’s strategies streamlined regulatory processes, enhanced site management, optimized patient selection and retention, and effectively managed investigational products (IP). By addressing these critical areas, the trial not only achieved its scientific objectives but also set a new benchmark for efficiency and success in the field of Biosimilar development. To know more about our Clinical Solutions, write to us at bd@cod-research.com Designing Therapies for Future #BiosimilarDevelopment #PhaseIIIClinicalTrial #DermatologyResearch #RegulatoryStrategy #SiteManagement #PatientRetention #ClinicalTrials #CODResearch

Just published in Dermatology and Therapy!! “Matching-Adjusted Indirect Comparison of the Efficacy at Week 32 of Tralokinumab and Dupilumab in the Treatment of Moderate-to-Severe Atopic Dermatitis” I’m happy to share our last publication (with Anne Sohrt Petersen, Ulla Ivens, PhD, Albert Bosch Vilaró, John Stinson and Jose Manuel Carrascosa Carrillo), where we conducted a matching adjusted indirect comparison of the efficacy at week 32 of tralokinumab and dupilumab in combination with topical corticosteroids (TCS). The results of this analysis showed that tralokinumab and dupilumab, both in combination with TCS, have similar efficacy at 32 weeks. Full paper: https://lnkd.in/d7t4XVEY #atopicdermatitis #biologictherapy

Thanks to the organizers of the 8th Annual Dermatology Drug Development Summit in Boston for inviting me to speak in the session devoted to "Optimizing the delivery of dermatological agents to increase targeting specificity in inflammatory environments".   Was a pleasure to highlight unmet needs in dermatology and innovative drug candidates in the pipeline of #AlysPharmaceuticals (www.alyspharma.com), including a unique #bispecific mAb that selectively antagonizes mast-cell c-Kit planned for clinical trials in chronic spontaneous urticaria, and a unique #siRNA platform technology with #Jak1 siRNA for transepidermal delivery and skin selective Jak1 silencing as its lead planned for clinical trials in atopic dermatitis. #ThibaudPortal, #JohnHarris, #BrianKim, #CraigMello, #CarineBlanchard, #ClaireBouixPeter, #EmmanuelVial, #JonnyFinlay, #OrlaCunningham

🌟 As 2024 comes to a close, Dermatology Times is taking a look back at the studies, therapies, and advances in prurigo nodularis this year. From the US FDA approval of nemolizumab to the largest clinical trial in PN to date, explore more below. ⬇️ https://lnkd.in/gzXQHb_8

Prescription Dermatology Therapeutics Market Strategies for Expansion Analysis Report: Opportunities and Challenges Ahead https://lnkd.in/eQ3s6sJK #marketanalysis #marketresearch #marketresearchreports #businessintelligence

NEW Live Webinar – Acne Vulgaris Therapeutic Update: Overview of the 2024 Treatment Guidelines on May 30th.  Over 50 million people in the US have acne, leading to $846 million in medical costs and $398 million in lost productivity. This live webinar will review acne vulgaris and its clinical features along with summarizing the 2024 American Academy of Dermatology Guidelines for this condition. Register Now - https://bit.ly/3JHDto4 FACULTY - Darrell Hulisz, RPh, PharmD #pharmacists #pharmacytechnicians #continuingeducation #livewebinar

‘As needed’ biologic therapy is when a person takes their biologic medication at the first sign of their psoriasis symptoms returning, rather than at regular continuous intervals. A new research summary which explores the acceptability of ‘as needed’ biologic therapy is now available on our website. The Research was conducted by St. John’s Institute of Dermatology, Guy's and St Thomas' NHS Foundation Trust and King's College. Take a look at the overview here https://ow.ly/w5o950SJ4u3 #PsoriasisTreatment #BiologicTherapy #DermatologyResearch #Biologics

Live Webinar – Acne Vulgaris Therapeutic Update: Overview of the 2024 Treatment Guidelines on May 30th.  Over 50 million people in the US have acne, leading to $846 million in medical costs and $398 million in lost productivity. This live webinar will review acne vulgaris and its clinical features along with summarizing the 2024 American Academy of Dermatology Guidelines for this condition. Learn More - https://bit.ly/3JHDto4 FACULTY - Darrell Hulisz, RPh, PharmD

Recruiting diverse participants for dermatology clinical trials poses unique challenges, as skin conditions can vary widely in severity, symptoms, and impact on quality of life. Addressing these challenges requires tailored recruitment approaches, thorough screening processes, and dedicated patient engagement to ensure success. Dermatological conditions affect millions worldwide, with clinical research playing a vital role in advancing treatment options and improving patient care. With numerous active or upcoming dermatology trials, a direct-to-patient recruitment strategy is essential for raising awareness and helping patients access the most suitable studies and care solutions. Discover the latest patient recruitment strategies for dermatology and learn how AutoCruitment can support your trial enrollment efforts!

🧬 𝐖𝐡𝐲 𝐝𝐨𝐞𝐬 #𝐌𝐨𝐥𝐞𝐜𝐮𝐥𝐚𝐫𝐃𝐢𝐚𝐠𝐧𝐨𝐬𝐭𝐢𝐜𝐬 𝐩𝐥𝐚𝐲 𝐚𝐧 𝐞𝐬𝐬𝐞𝐧𝐭𝐢𝐚𝐥 𝐫𝐨𝐥𝐞 𝐢𝐧 𝐝𝐞𝐫𝐦𝐚𝐭𝐨𝐥𝐨𝐠𝐲? In recent decades, the development of novel and highly specific therapeutics has increased a lot in dermatology, especially for conditions such as melanoma, psoriasis, and eczema. However, diagnostic techniques have not advanced at the same pace, preventing highly specific therapeutics from reaching their full potential. This large gap between diagnostics and therapeutics is being bridged by DNA- and RNA-based molecular diagnostics. Dermagnostix started on building this bridge with #PsorX – the worldwide first molecular test for the differential diagnosis of psoriasis and eczema! You want to join our journey of #MovingDiagnosticFrontiers in dermatology? Subscribe to our #newsletter: https://lnkd.in/eRCXcTVB #BeyondTheSurface #Psoriasis #Eczema